Stocks Health care GRI
NASDAQ · Health careGRI Bio, Inc. (GRI)
It posted a net loss of $9.7M. In fiscal 2025 capital spending exceeded operating cash flow by $10.2M. At June 30, 2026 it held $10.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about GRI Bio, Inc.
- Net worth
- GRI Bio, Inc. has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $10.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2021 revenue was $0 (-100.0% year on year), with a net loss of $9.3M.
- Cash flow
- In fiscal 2025 operations used $10.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- GRI Bio, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What GRI Bio, Inc. does
GRI Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GRI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$12M | -$121.80 | -$10.2M |
| 2024 | n/a | -$8.2M | -$1,545.55 | -$8.6M |
| 2023 | n/a | -$13M | -$140,476.53 | -$9M |
| 2022 | n/a | -$3.2M | -$124,066.88 | -$1.1M |
| 2021 | $0 | -$9.3M | -$255,326.04 | -$8.3M |
| 2021 | $100K | -$4.8M | -$192,393.57 | -$3.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What GRI Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026
- September 28, 2026Proxy statement DEF 14A
- September 8, 2026
- August 14, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- June 18, 2026Other event 8-K
- May 14, 2026
- May 13, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- February 13, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running GRI Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about GRI
What does GRI Bio, Inc. do?
GRI Bio, Inc. is a company in the Health care sector, listed on NASDAQ as GRI. Its shares trade on NASDAQ under the ticker GRI.
What is GRI Bio, Inc.'s net worth?
GRI Bio, Inc. has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $10.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is GRI Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $9.7M.
When did GRI Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from September 28, 2026.
When is GRI Bio, Inc.'s next earnings report?
GRI Bio, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GRI with
Follow GRI
Get an email when GRI Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values GRI Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.